SCHEMBL1316825

SCHEMBL1316825

CC(C)(C)OC(=O)c1ccc(-c2ccccc2)cc1NC(=O)c1ccc(-c2ccncc2)cc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 5/20 0.52
▸ NOX1 Q9Y5S8 2/20 0.44
▸ CDC7 O00311 1/20 0.44
▸ ROCK2 O75116 1/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ CLK4 Q9HAZ1 1/20 0.44
▸ MKNK2 Q9HBH9 1/20 0.44
▸ MAPK14 Q16539 1/20 0.42
▸ SMO Q99835 1/20 0.42
▸ SGMS2 Q8NHU3 3/20 0.42
▸ MCL1 Q07820 1/20 0.42
▸ HDAC1 Q13547 2/20 0.42
▸ GPR142 Q7Z601 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RXRA P19793 1/20 0.40
▸ NR1H2 P55055 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1316898 0.94 MCL1 (0.47) LRRK2SGMS2MCL1HDAC1MEN1
SCHEMBL1316125 0.94 LRRK2 (0.61) LRRK2NOX1CDC7ROCK2MAP4K4
SCHEMBL1318330 0.92 LRRK2 (0.52) LRRK2MKNK2SGMS2HDAC1
SCHEMBL1315304 0.90 SGMS2 (0.45) LRRK2MAPK14SMOSGMS2MCL1
SCHEMBL1317655 0.90 GAA (0.46) LRRK2SGMS2MCL1HDAC1MEN1
SCHEMBL1317041 0.89 HDAC1 (0.43) LRRK2SGMS2MCL1HDAC1MEN1
SCHEMBL1315346 0.88 HDAC1 (0.42) LRRK2SGMS2MCL1HDAC1HDAC2
SCHEMBL1316899 0.87 GAA (0.43) LRRK2SGMS2MCL1HDAC1MEN1
SCHEMBL1320022 0.86 PPARD (0.43) LRRK2SGMS2MCL1HDAC1HDAC2
SCHEMBL1317043 0.86 NR1H2 (0.43) LRRK2SGMS2MCL1HDAC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102333757-B N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD 2014-11-26 — — CN disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 — — US disclosed
CN-102333757-A N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD 2012-01-25 — — CN disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 — — US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 LRRK2 1813/4885NOX1 214/4885CDC7 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback